Conferences - Results from #20

ASCO 2023: PROPELLER: 64Cu-SAR-bisPSMA PET Imaging in Patients with Confirmed Prostate Cancer June 5, 2023

ASCO 2023: Concurrent Chemo-Hormonal Therapy of Enzalutamide and Cabazitaxel in Patients with mCRPC: Final Analysis of ORR, rPFS, and OS June 5, 2023

ASCO 2023: Independent Biomarkers Predictive of Outcomes with Enfortumab Vedotin in Patients with Advanced Urothelial Carcinoma: Analysis of the UNITE Study June 5, 2023

ASCO 2023: Biomarkers of Response to Sacituzumab Govitecan and Efficacy After Treatment with Enfortumab Vedotin in Advanced Urothelial Carcinoma: Analysis of the UNITE Study June 5, 2023

ASCO 2023: Final Results from SAUL, a Single-Arm International Real-World Study of Atezolizumab in Patients with Pretreated Locally Advanced/Metastatic UTC June 5, 2023

ASCO 2023: Enfortumab Vedotin with or Without Pembrolizumab in Patients Who Are Cisplatin-Ineligible with Previously Untreated Locally Advanced or Metastatic Urothelial Cancer: Additional 3-Month Follow-up on Cohort K Data June 5, 2023

ASCO 2023: Pathologic Concordance Rate and Outcomes by Histologic Subtype in Advanced Papillary Renal Cell Carcinoma: An Analysis from the SWOG S1500 (PAPMET) Trial June 5, 2023

ASCO 2023: Discussant: Germinating Data for Germ Cell Tumors June 5, 2023

ASCO 2023: Discussant: DDR and PARP Inhibition: What's the Damage? June 5, 2023

ASCO 2023: PSMAddition: A Phase 3 Trial to Compare Treatment with 177Lu-PSMA-617 + Standard of Care and Standard of Care Alone in Patients with mHSPC June 5, 2023

ASCO 2023: TALAPRO-2: Phase 3 Study of Talazoparib + Enzalutamide Versus Placebo + ENZA as First-Line Treatment for Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Harboring Homologous Recombination Repair (HRR) Gene Alterations June 5, 2023

ASCO 2023: Presence of Somatic/Germline Homologous Recombination Repair Mutations and Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Receiving First‑line Treatment Stratified by BRCA Status June 5, 2023

ASCO 2023: LuPARP: Phase 1 Trial of 177Lu-PSMA-617 and Olaparib in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) June 5, 2023

ASCO 2023: Phase 1b/2 Study of Combination 177Lu Girentuximab + Cabozantinib and Nivolumab in Treatment Naïve Patients with Advanced Clear Cell RCC June 5, 2023

ASCO 2023: Discussant: Advanced Urothelial Carcinoma: Striking a Balance of Efficacy and Safety June 4, 2023

ASCO 2023: Primary RPLND in Seminoma Stage IIA-IIC ≤3cm: Combined Results of the SWENOTECA (Swedish Norwegian Testicular Cancer Group) and Cologne June 4, 2023

ASCO 2023: Molecular Drivers of Organotropism and Cisplatin Resistance in Germ Cell Tumors June 4, 2023

ASCO 2023: Discussant: Hitting the Sweet Spot with Radiation and Androgen Deprivation June 4, 2023

ASCO 2023: Real-World Safety and Effectiveness of Radium-223 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated in the US: The Non-Interventional REASSURE Study June 4, 2023

ASCO 2023: Discussant: The Power of Patients' Experiences to Inform Therapeutic Decisions June 4, 2023

Page 2 of 522